Sutro Biopharma Revenue vs. Net Income
| STRO Stock | USD 2.51 0.02 0.79% |
Total Revenue | First Reported 2016-12-31 | Previous Quarter 25.7 M | Current Value 8.5 M | Quarterly Volatility 20.5 M |
For Sutro Biopharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Sutro Biopharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Sutro Biopharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Sutro Biopharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Sutro Biopharma over time as well as its relative position and ranking within its peers.
Sutro |
Sutro Biopharma's Revenue Breakdown by Earning Segment
Check out World Market Map.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sutro Biopharma. If investors know Sutro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sutro Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.55) | Revenue Per Share 2.253 | Quarterly Revenue Growth (0.50) | Return On Assets (0.18) | Return On Equity (1.11) |
The market value of Sutro Biopharma is measured differently than its book value, which is the value of Sutro that is recorded on the company's balance sheet. Investors also form their own opinion of Sutro Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sutro Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sutro Biopharma's market value can be influenced by many factors that don't directly affect Sutro Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sutro Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sutro Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sutro Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Sutro Biopharma Net Income vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Sutro Biopharma's current stock value. Our valuation model uses many indicators to compare Sutro Biopharma value to that of its competitors to determine the firm's financial worth. Sutro Biopharma is currently regarded number one company in revenue category among its peers. It is rated below average in net income category among its peers . At this time, Sutro Biopharma's Total Revenue is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sutro Biopharma's earnings, one of the primary drivers of an investment's value.Sutro Revenue vs. Competition
Sutro Biopharma is currently regarded number one company in revenue category among its peers. Market size based on revenue of Health Care industry is at this time estimated at about 273.42 Million. Sutro Biopharma totals roughly 153.73 Million in revenue claiming about 56% of equities under Health Care industry.
Sutro Net Income vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Sutro Biopharma |
| = | 153.73 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Sutro Biopharma |
| = | (106.79 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Sutro Net Income Comparison
Sutro Biopharma is currently under evaluation in net income category among its peers.
Sutro Biopharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Sutro Biopharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Sutro Biopharma will eventually generate negative long term returns. The profitability progress is the general direction of Sutro Biopharma's change in net profit over the period of time. It can combine multiple indicators of Sutro Biopharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 21 K | 22.1 K | |
| Net Interest Income | -2.2 M | -2.1 M | |
| Interest Income | 12.1 M | 12.7 M | |
| Operating Income | -89.3 M | -93.7 M | |
| Net Loss | -172.5 M | -163.8 M | |
| Income Before Tax | -88.6 M | -93 M | |
| Total Other Income Expense Net | 677 K | 643.1 K | |
| Net Loss | -107.3 M | -101.9 M | |
| Net Loss | -106.8 M | -101.5 M | |
| Income Tax Expense | 18.2 M | 19.1 M | |
| Non Operating Income Net Other | 519.3 K | 493.3 K | |
| Change To Netincome | 14.6 M | 15.3 M | |
| Net Loss | (1.78) | (1.86) | |
| Income Quality | 1.05 | 1.10 | |
| Net Income Per E B T | 1.21 | 0.88 |
Sutro Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Sutro Biopharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Sutro Biopharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Sutro Biopharma's important profitability drivers and their relationship over time.
Use Sutro Biopharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sutro Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sutro Biopharma will appreciate offsetting losses from the drop in the long position's value.Sutro Biopharma Pair Trading
Sutro Biopharma Pair Trading Analysis
The ability to find closely correlated positions to Sutro Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sutro Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sutro Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sutro Biopharma to buy it.
The correlation of Sutro Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sutro Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sutro Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sutro Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Sutro Biopharma position
In addition to having Sutro Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Retail Thematic Idea Now
Retail
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Retail theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Retail Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map. To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
To fully project Sutro Biopharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Sutro Biopharma at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Sutro Biopharma's income statement, its balance sheet, and the statement of cash flows.